Background: Recently, several clinical studies have evaluated the first-line use of immune checkpoint inhibitors (ICIs) combined with platinum-doublet chemotherapy in patients non-squamous non-small cell lung cancer (NSCLC), however, differences safety and efficacy between various types ICIs still require investigation. In this study, we NSCLC by meta-analysis indirect comparison.

Introduction: Lung cancer is the disease of modern era, and the rate of lung cancer mortality is three times as high as that for prostate cancer and twice as high as the rate for breast cancer. We aimed to analyze the results of pulmonary resection in patients with NSCLC by minimally invasive thoracoscopy.  Materials and Methods: We studied 10 patients with NSCLC scheduled for surgical resectio...

BACKGROUND The role of histology in the targeted management of nonsmall cell lung cancer (NSCLC) has garnered renewed attention in recent years. We provide contemporary population-based estimates of survival and an assessment of important prognostic factors in stage IV NSCLC by major histologic subtype. METHODS Using data from the Surveillance, Epidemiology and End Results (SEER) Program, we ...

Defects in the apoptotic machinery may contribute to chemoresistance of nonsmall cell lung cancer (NSCLC) cells. We have previously demonstrated a deficiency in mitochondria-dependent caspase-9 activation in NSCLC H460 cells after exposure to cisplatin, a drug widely used to treat NSCLC. Here we show that, unlike cisplatin, the novel anticancer agent bortezomib efficiently induces caspase-9 act...

Purpose Nivolumab is one of the most extensively studied immune checkpoint inhibitors across various tumor types. In this narrative review, the current clinical efficacy and safety data of anti-programmed death-1 (PD-1) nivolumab for nonsmall cell lung cancer (NSCLC) and renal cell cancer (RCC) are elucidated. Methods Systematic search was done on Pubmed, Medline, Embase, Web of Knowledge, an...

PURPOSE We report surgical results of metachronous nonsmall cell lung cancer (NSCLC). METHODS We report mortality and analyze prognostic factors for overall survival in patients with metachronous NSCLC at Nippon Medical School from July 1982 to July 2008. RESULTS Thirty-three out of 1726 patients (1.9%) who underwent lung resection had metachronous NSCLC. Mortality rate was 10%. On univaria...

Epidermal growth factor receptor (EGFR) tumour genotyping is crucial to guide treatment decisions regarding the use of EGFR tyrosine kinase inhibitors in nonsmall cell lung cancer (NSCLC). However, some patients may not be able to obtain tumour testing, either because tissue is limited and/or tests are not routinely offered. Here, we aimed to build a model-based nomogram to allow for prediction...

Background: Nowadays, the influence of anesthesia management on prognosis cancer patients has been widely concerned. The goal this study is to assess association between anesthetic factors and with non-small cell lung (NSCLC) after surgery.